太平洋医药日报（20260304）：FDA 授予 Brepocitinib 优先审评 资格 ◼ 走势比较 (10%) (2%) 6% 14% 22% 30% 25/3/4 25/5/16 25/7/28 25/10/9 25/12/21 26/3/4 2026 年 03 月 04 日 行业日报 看好/维持 医药 医药 相关研究报告 <<太平洋医药日报（20260303）：礼来 Lebrikizumab 在 华 申 报 上 市 >>-- 2026-03-04 <<太平洋医药日报（20260302）：多肽 药 Yuviwel 获 FDA 批准上市>>-- 2026-03-04 <<太平洋医药日报（20260227）： Zongertinib 获 FDA 加速批准>>-- 2026-03-01 证券分析师：周豫 电话： E-MAIL：zhouyua@tpyzq.com 分析师登记编号：S1190523060002 证券分析师：张崴 电话： E-MAIL：zhangwei@tpyzq.com 分析师登记编号：S1190524060001 报告摘要 市场表现： 2025年3月4日，医药板块涨跌幅-1.12%，跑赢沪深3 ...

经济观察网 基于公开信息，东阳光药（06887.HK）在2026年及近期有以下值得关注的事件动态，主要 涉及产品获批、研发进展及市场格局变化。以下内容整理自公开资料，事件时间线以最新公告为准。 近期受关注事件 仿制药市场准入与专利到期 富马酸伏诺拉生片（原研为武田制药的P-CAB药物）于2026年1月30日获批仿制并视同通过一致性评 价，为2026年8月29日专利到期后的市场放量做准备。目前国内已有39家企业获批该品种，专利到期后 可能面临价格竞争。 原研药份额在专利到期后可能快速下滑，仿制药价格下行压力凸显，市场对东阳光药长期盈利能力存在 分歧。 甘精胰岛素在美国市场的BLA批准预计在2026年上半年完成，门冬胰岛素也计划于2026年底获批，助力 国际化布局。 2026年1月，SGLT-2抑制剂奥洛格列淨胶囊获批上市，并与晶泰科技合作AI药物研发平台，形成短期催 化。 业务与技术发展 技术平台与战略合作 公司于2026年1月推出面向PROTAC机制的AI智能研发平台，整合临床管线数据，首个AI驱动小分子药 物HEC169584已进入临床I期。 通过海外BD合作加速国际化，如2024年11月与英国Apollo ...

Company Overview - Dongyang Sunshine Pharmaceutical (东阳光药) received approval for Fumaric Acid Vonoprazan Tablets on January 30, 2026, leading to stock price fluctuations influenced by product approval and market expectations regarding competition and profitability [1] - The company's core product, Oseltamivir Phosphate (可威), is expected to account for over 60% of revenue in the first half of 2025, but is projected to decline by 37.1% in 2024 due to procurement issues [4] Industry Analysis - The generic drug market is highly competitive, with 39 companies already approved for the same product and an additional 69 companies under review, indicating potential price wars and profit margin compression post-patent expiration [3] - Takeda Pharmaceutical currently holds a monopoly in the market, but its market share is expected to decline rapidly after the patent protection period ends on August 29, 2026, leading to downward pressure on generic drug prices [3] Financial Performance - The company's price-to-earnings ratio (TTM) is negative at -57.55, reflecting ongoing profitability challenges [4] - On February 12, during a stock price drop, trading volume surged to 20.49 million HKD, indicating increased market volatility and diverging opinions among investors [4] Market Trends - The biopharmaceutical sector has seen a decline, with the A-share biopharmaceutical index dropping by 3.52% over the past 20 days, while the Hong Kong Hang Seng Index fell by 1.72%, suggesting weak industry sentiment [5] - Over the last 20 trading days, southbound funds have seen a net reduction of 38,060 shares, indicating short-term pressure on capital [6]

Meeting Overview - The first meeting of the 10th Board of Directors of China National Pharmaceutical Group Co., Ltd. was held on February 9, 2026, combining in-person and communication methods [2] - All 8 directors attended the meeting, and the meeting complied with the relevant provisions of the Company Law and Articles of Association, making the resolutions valid [4][5] Resolutions Passed - The board elected Mr. Yang Guang as the Chairman and legal representative of the company, with a term from the date of approval until the end of the 10th Board's term [6] - The board approved the election of members for various specialized committees, including: - Strategy and ESG Committee: Mr. Yang Guang (Chairman), Mr. Pan Zhen, Mr. Li Zhiyong, Mr. Fan Xiongtao - Audit and Risk Control Committee: Mr. Wang Ruihua (Chairman), Ms. Yan Yonghong, Mr. Fan Xiongtao - Nomination Committee: Ms. Yan Yonghong (Chairman), Mr. Wang Ruihua, Mr. Yang Guang - Compensation and Assessment Committee: Mr. Li Zhiyong (Chairman), Mr. Wang Ruihua, Ms. Sun Zhuo [8][10] - The board appointed Mr. Yang Guang as the General Manager, with a term from the date of approval until the end of the 10th Board's term [12] - The board approved the appointment of senior management personnel, including: - Mr. Zhang Peng and Mr. Chen Jianxiong as Vice General Managers - Ms. Ge Xiaohong as Chief Accountant - Mr. Zhang Huibo and Mr. Lü Heping as Assistant General Managers - Mr. Zhang Jian as Chief Legal Advisor [14][15] - The board appointed Mr. Yuan Jinghua as the Secretary of the Board and Ms. Guo Fan as the Securities Affairs Representative [17][19] - The board approved the renewal of the office lease for the General Times Center for one year, with a total rental amount not exceeding 62.2451 million yuan (including tax) [21][37] Office Lease Details - The lease agreement is with China General Technology (Group) Holding Limited and its property management company, covering the period from January 1, 2026, to December 31, 2026 [37] - The total rental and property service fees are expected to be no more than 72.1593 million yuan [37] - The rental price remains unchanged compared to 2025, based on market pricing and surrounding office buildings [39][52] New Drug Registration - The company’s subsidiary, Tianfang Pharmaceutical Co., Ltd., received two drug registration certificates for fumaric acid volnoreline tablets from the National Medical Products Administration [64] - The drug is primarily used for treating reflux esophagitis and eradicating Helicobacter pylori when used with appropriate antibiotics [65] - The total investment in the drug's raw materials and formulation projects is approximately 12.32 million yuan [67] - The market for this drug is projected to have sales of approximately 774 million yuan in 2024 and 778 million yuan in the first three quarters of 2025 [68]

Core Viewpoint - China National Pharmaceutical Group Co., Ltd. announced the approval of fumaric acid volnorelaxin tablets by the National Medical Products Administration, marking a significant step in the company's integrated layout of raw materials and formulations [1] Group 1: Product Approval and Specifications - The approved specifications for the drug are 10mg and 20mg, primarily used for treating reflux esophagitis and eradicating Helicobacter pylori in conjunction with antibiotics [1] - The total investment in the raw material and formulation project for this drug amounts to approximately 12.32 million RMB [1] Group 2: Market Potential and Sales Forecast - According to data from Minet, the estimated sales revenue for this drug in China's three major terminal markets is approximately 774 million RMB in 2024, with sales of about 778 million RMB in the first three quarters of 2025 [1] - Currently, a total of 40 production enterprises, including Tianfang Pharmaceutical, have obtained approval for this drug [1] Group 3: Strategic Implications - The approval is expected to enrich the company's product line and enhance its business layout [1] - Future sales performance may be influenced by uncertainties related to national policies and market conditions [1]

Core Viewpoint - The announcement highlights the approval of two drug registration certificates for Fumaric Acid Vonoprazan Tablets by Tianfang Pharmaceutical, a wholly-owned subsidiary of China Pharmaceutical, indicating a significant development in the company's product portfolio and market presence in the treatment of gastroesophageal reflux disease and Helicobacter pylori eradication [1] Group 1 - The drug is primarily used for treating gastroesophageal reflux disease and in combination with appropriate antibiotics to eradicate Helicobacter pylori [1] - The drug was developed by Takeda Pharmaceutical and was launched in Japan in December 2014, followed by its introduction to the Chinese market in December 2019 [1] - As of the announcement date, a total of 39 domestic manufacturers, including Tiandi Hengyi Pharmaceutical Co., Ltd. and Guangdong Dongyangguang Pharmaceutical Co., Ltd., have obtained production licenses for this drug [1]

Group 1 - The core point of the article is that Shuanglu Pharmaceutical (002038.SZ) has received approval from the drug regulatory authority for its fumaric acid volnorex tablets [1] Group 2 - The approval indicates a significant milestone for the company, potentially enhancing its product portfolio and market presence [1] - This development may lead to increased investor interest and confidence in the company's future growth prospects [1] - The approval aligns with the company's strategy to expand its offerings in the pharmaceutical market [1]

Policy Developments - The National Health Commission and five other departments launched a one-year special campaign against illegal ambulances, targeting both registered "ambulance" vehicles and unregistered "black ambulances" [2] - The campaign includes comprehensive inspections, management principles, and encourages social participation in medical transport services [2][3] Drug and Medical Device Approvals - Aied Bio received a medical device registration certificate for its gene mutation detection kit, which is now approved in China, Japan, and Europe, aiding non-small cell lung cancer patients [4] - Hainan Haiyao's subsidiary obtained a drug registration certificate for Fumaric Acid Vonoprazan Tablets, the first P-CAB for reflux esophagitis in China [5] Capital Market Activities - China National Pharmaceutical Modern signed a drug listing license transfer contract for Lactulose Oral Solution, with a total transfer fee of 5.86 million yuan, projected to generate 2.069 billion yuan in sales in 2024 [6] - Jiangsu Hengrui Medicine and Neurocrine Biosciences entered a collaboration for developing NLRP3 inhibitors, with a potential total value of $881.5 million [7][8] Industry Events - The 2025 medical insurance negotiation concluded, with results expected to be announced in early December [9] - The only approved stem cell drug in China, Aimi Maito Sai Injection, is included in the "Beijing Universal Health Insurance" with a maximum reimbursement of 65% [10] Regulatory Issues - The executive director of CSPC Pharmaceutical Group was fined 5 million yuan for insider trading related to a merger announcement [11]

Company Announcements - Strong瑞技术 plans to invest 70 million yuan to acquire a 35% stake in liquid cooling company Alubao Technology, which indirectly supplies AI servers to Nvidia [1][2] - China Mobile's controlling shareholder, China Mobile Group, intends to transfer 41.98 million shares of the company to China National Petroleum Group [1][2] - Pingtan Development's main business involves activities related to the open development of the Pingtan Comprehensive Experimental Zone [1][2] Focus of the Day - Shengyi Technology's largest shareholder, Guangxin Group, and executives plan to reduce their holdings by no more than 1.03% of the company's shares [3] - Siwei Liekong's director and deputy general manager Zhao Jianzhou has been detained and is under investigation [3] - Huya Technology has signed a strategic cooperation agreement with Tailan New Energy to collaborate on adhesives in the solid-state battery sector [3] Shareholding Changes - Dagang Co. plans to invest 90 million yuan to increase its stake in chip testing company Aike Integrated to 78.79% [4] - Sanhua Intelligent Control has repurchased 1.9361 million shares as of October 31, totaling nearly 56 million yuan [3][4] Financial Performance - China Shenhua will distribute a total cash dividend of 19.471 billion yuan for the first half of 2025 [3] Financing and Capital Increase - Juhe Materials is planning to issue H-shares and list on the Hong Kong Stock Exchange [3] Contracts and Projects - Han Jian Heshan has signed a procurement contract worth 207 million yuan with China Nuclear Industry Huaxing Construction Co., accounting for 26.29% of the audited revenue for 2024 [3] Other Developments - ST Jingang has received a total of 1.804 billion yuan from all restructuring investors [8] - Long Spring High-tech's subsidiary has received approval for clinical trials of GenSci134 injection for treating idiopathic short stature [8]

Core Viewpoint - Hainan Haiyao's subsidiary has received approval for a new chemical drug, indicating potential growth in its pharmaceutical portfolio and market presence [1] Group 1: Company Developments - Hainan Haiyao's wholly-owned subsidiary, Haikou Pharmaceutical Factory Co., Ltd., has obtained the Drug Registration Certificate for "Fumaric Acid Vonoprazan Tablets" from the National Medical Products Administration [1] - The registered indication for the drug is gastroesophageal reflux disease, which can be used in conjunction with appropriate antibiotics to eradicate Helicobacter pylori [1]